NCT07053735View on ClinicalTrials.gov

An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Bladder (Urothelial, Transitional Cell) Cancer
Interventions
DRUG

Nimotuzumab and Radiotherapy

"1. nimotuzumab: 200mg, iv, qw, used for 5 weeks.~2. radiotherapy: radiotherapy is performed according to clinical routine;"

All Listed Sponsors
lead

Peking University First Hospital

OTHER